These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 27931968)

  • 41. New Treatment Options and Management Considerations in Borderline Resectable Pancreatic Cancer.
    Jutric Z; Melstrom LG
    Oncology (Williston Park); 2017 Jun; 31(6):443-52. PubMed ID: 28620900
    [TBL] [Abstract][Full Text] [Related]  

  • 42. FDG-PET predicts treatment efficacy and surgical outcome of pre-operative chemoradiation therapy for resectable and borderline resectable pancreatic cancer.
    Akita H; Takahashi H; Ohigashi H; Tomokuni A; Kobayashi S; Sugimura K; Miyoshi N; Moon JH; Yasui M; Omori T; Miyata H; Ohue M; Fujiwara Y; Yano M; Ishikawa O; Sakon M
    Eur J Surg Oncol; 2017 Jun; 43(6):1061-1067. PubMed ID: 28389044
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multimodality Therapy in Patients With Borderline Resectable or Locally Advanced Pancreatic Cancer: Importance of Locoregional Therapies for a Systemic Disease.
    Tsai S; Christians KK; Ritch PS; George B; Khan AH; Erickson B; Evans DB
    J Oncol Pract; 2016 Oct; 12(10):915-923. PubMed ID: 27858562
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Therapeutic Strategy for Resectable Pancreatic Cancer Based on Risk Factors of Early Recurrence.
    Kurahara H; Maemura K; Mataki Y; Sakoda M; Iino S; Kawasaki Y; Arigami T; Mori S; Kijima Y; Ueno S; Shinchi H; Natsugoe S
    Pancreas; 2018 Jul; 47(6):753-758. PubMed ID: 29771771
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
    Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
    Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [A Case of R0 Resection of Locally Advanced Pancreatic Cancer Following Chemoradiation Therapy].
    Miyahara Y; Okamura D; Nishida T; Shimizu H; Ohtsuka M; Kato A; Yoshitomi H; Furukawa K; Takayashiki T; Kuboki S; Takano S; Suzuki D; Sakai N; Kagawa S; Miyazaki M
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):2382-4. PubMed ID: 26805371
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Therapy of locally advanced pancreatic adenocarcinoma: unresectable and borderline patients.
    Kircher SM; Krantz SB; Nimeiri HS; Mulcahy MF; Munshi HG; Benson AB
    Expert Rev Anticancer Ther; 2011 Oct; 11(10):1555-65. PubMed ID: 21999129
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neoadjuvant chemo-radiotherapy for patients with borderline resectable pancreatic cancer: a meta-analytical evaluation of prospective studies.
    Festa V; Andriulli A; Valvano MR; Uomo G; Perri F; Andriulli N; Corrao S; Koch M
    JOP; 2013 Nov; 14(6):618-25. PubMed ID: 24216547
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?
    Papalezova KT; Tyler DS; Blazer DG; Clary BM; Czito BG; Hurwitz HI; Uronis HE; Pappas TN; Willett CG; White RR
    J Surg Oncol; 2012 Jul; 106(1):111-8. PubMed ID: 22311829
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neoadjuvant vs adjuvant therapy for resectable pancreatic cancer: the evolving role of radiation.
    Hoffe S; Rao N; Shridhar R
    Semin Radiat Oncol; 2014 Apr; 24(2):113-25. PubMed ID: 24635868
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Radiographic Splenic Artery Involvement Is a Poor Prognostic Factor in Upfront Surgery for Patients with Resectable Pancreatic Body and Tail Cancer.
    Kawai M; Hirono S; Okada KI; Miyazawa M; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Yamaue H
    Ann Surg Oncol; 2021 Mar; 28(3):1521-1532. PubMed ID: 32705517
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Evidence for Neoadjuvant Therapy in Resectable Pancreatic Cancer].
    Nießen A; Büchler MW; Hackert T
    Zentralbl Chir; 2022 Apr; 147(2):168-172. PubMed ID: 35378557
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Multimodality Management of "Borderline Resectable" Pancreatic Neuroendocrine Tumors: Report of a Single-Institution Experience.
    Ambe CM; Nguyen P; Centeno BA; Choi J; Strosberg J; Kvols L; Hodul P; Hoffe S; Malafa MP
    Cancer Control; 2017; 24(5):1073274817729076. PubMed ID: 28975822
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Borderline resectable pancreatic cancer: pushing the technical limits of surgery.
    Katz MH; Ahmad S; Nelson H
    Bull Am Coll Surg; 2013 Jan; 98(1):61-3. PubMed ID: 23359915
    [No Abstract]   [Full Text] [Related]  

  • 55. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design.
    Katz MH; Marsh R; Herman JM; Shi Q; Collison E; Venook AP; Kindler HL; Alberts SR; Philip P; Lowy AM; Pisters PW; Posner MC; Berlin JD; Ahmad SA
    Ann Surg Oncol; 2013 Aug; 20(8):2787-95. PubMed ID: 23435609
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy.
    Mellon EA; Jin WH; Frakes JM; Centeno BA; Strom TJ; Springett GM; Malafa MP; Shridhar R; Hodul PJ; Hoffe SE
    Acta Oncol; 2017 Mar; 56(3):391-397. PubMed ID: 27885876
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy.
    Barugola G; Partelli S; Crippa S; Capelli P; D'Onofrio M; Pederzoli P; Falconi M
    Am J Surg; 2012 Feb; 203(2):132-9. PubMed ID: 21824596
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Outcomes after extended pancreatectomy in patients with borderline resectable and locally advanced pancreatic cancer.
    Hartwig W; Gluth A; Hinz U; Koliogiannis D; Strobel O; Hackert T; Werner J; Büchler MW
    Br J Surg; 2016 Nov; 103(12):1683-1694. PubMed ID: 27686238
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Pancreatic cancer - current effective diagnostic and therapeutic approach].
    Ryska M
    Cas Lek Cesk; 2016; 155(1):38-43. PubMed ID: 26898790
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Management of borderline resectable pancreatic cancer.
    Katz MH; Crane CH; Varadhachary G
    Semin Radiat Oncol; 2014 Apr; 24(2):105-12. PubMed ID: 24635867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.